Isabelle Meyts, Christopher C. Dvorak, Morna J. Dorsey, Antonio Condino-Neto, Hassan Abolhassani, Rongras Damrongwatanasuk, Reinhard Seger, John M. Routes, Trudy N. Small, Hans D. Ochs, Maria Kanariou, Carsten Speckmann, Beatriz Tavares Costa Carvalho, J. David M. Edgar, Luis Ignacio Gonzalez-Granado, Andrew R. Gennery, Victor M. Aquino, M. Teresa de la Morena, Ramsay Fuleihan, Gisela Seminario, Nancy Bunin, Neena Kapoor, Chaim M. Roifman, Alan P. Knutsen, Helen Chapel, Jiri Litzman, Lisa Kobrynski, Liliana Bezrodnik, Anna Shcherbina, Teresa Espanol, Paul Gray, Francisco A. Bonilla, Janet Chou, Andrew J. Cant, Imelda C. Hanson, Luis Murguia-Favela, Troy R. Torgerson, Christian A. Wysocki, Fatima Dhalla, Mary Slatter, Eyal Grunebaum, Andrea C. Gómez Raccio, Necil Kutukculer, Jordan K. Abbott, David Leonard, Evangelia Farmaki, Joris M. van Montfrans, Srdjan Pasic, Sharat Chandra, Ales Janda, Luigi D. Notarangelo, Melanie Wong, Otavio Cabral-Marques, M.J. Cowan, Caroline Y. Kuo, Alexandra H. Filipovich, Asghar Aghamohammadi, John W. Sleasman, Darko Richter, Karin Chen, Suranjith L. Seneviratne, Charlotte Cunningham-Rundles, Daniela DiGiovanni, and Ege Üniversitesi
WOS: 000398771800023, PubMed ID: 27697500, Background: X-linked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency with high morbidity and mortality compared with those seen in healthy subjects. Hematopoietic cell transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complications and might not be available for all patients. Objectives: We sought to collect data on the clinical presentation, treatment, and follow-up of a large sample of patients with XHIGM to (1) compare long-term overall survival and general well-being of patients treated with or without HCT along with clinical factors associated with mortality and (2) summarize clinical practice and risk factors in the subgroup of patients treated with HCT. Methods: Physicians caring for patients with primary immunodeficiency diseases were identified through the Jeffrey Modell Foundation, United States Immunodeficiency Network, Latin American Society for Immunodeficiency, and Primary Immune Deficiency Treatment Consortium. Data were collected with a Research Electronic Data Capture Web application. Survival from time of diagnosis or transplantation was estimated by using the Kaplan-Meier method compared with log-rank tests and modeled by using proportional hazards regression. Results: Twenty-eight clinical sites provided data on 189 patients given a diagnosis of XHIGM between 1964 and 2013; 176 had valid follow-up and vital status information. Sixty-seven (38%) patients received HCT. The average follow-up time was 8.5 +/- 7.2 years (range, 0.1-36.2 years). No difference in overall survival was observed between patients treated with or without HCT (P = .671). However, risk associated with HCT decreased for diagnosis years 1987-1995; the hazard ratio was significantly less than 1 for diagnosis years 1995-1999. Liver disease was a significant predictor of overall survival (hazard ratio, 4.9; 95% confidence limits, 2.2-10.8; P < .001). Among survivors, those treated with HCT had higher median Karnofsky/Lansky scores than those treated without HCT (P < .001). Among patients receiving HCT, 27 (40%) had graft-versus-host disease, and most deaths occurred within 1 year of transplantation. Conclusion: No difference in survival was observed between patients treated with or without HCT across all diagnosis years (1964-2013). However, survivors treated with HCT experienced somewhat greater well-being, and hazards associated with HCT decreased, reaching levels of significantly less risk in the late 1990s. Among patients treated with HCT, treatment at an early age is associated with improved survival. Optimism remains guarded as additional evidence accumulates., Jeffrey Modell Foundation; National Institutes of Health Office of Rare Diseases, National Center for Advancing Translational Sciences and National, Institute of Allergy and Infectious Disease [U54 AI 082973, R13AI094943], Supported by a grant from Jeffrey Modell Foundation (to M.d.l.M.). The Primary Immune Deficiency Treatment Consortium (PIDTC) is supported by the National Institutes of Health Office of Rare Diseases, National Center for Advancing Translational Sciences and National, Institute of Allergy and Infectious Disease grants U54 AI 082973 and R13AI094943.